[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-small-cell-lung-cancernsclc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-small-cell-lung-cancernsclc":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100541660","phase-1-study-to-evaluate-lb-lr1109-administered-alone-for-the-treatment-of-solid-tumor-and-in-combination-with-atezolizumab-for-the-treatment-of-nsclc-100541660",false,"NCT06332755","Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC","A Phase 1a\u002F1b, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109, When Administered Alone for the Treatment of Advanced or Metastatic Solid Tumors, and in Combination With Atezolizumab for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)","LB-LR1109","Key Inclusion Criteria:\n\n1. Age ≥18 years old at the time of signing the ICF.\n2. (Phase 1a only) Participants must have 1 of the following histologically confirmed advanced or metastatic solid tumors with measurable or non-measurable disease as determined by RECIST v1.1,\n\n   \\- NSCLC, HNSCC, RCC, urothelial carcinoma, or malignant melanoma.\n3. (Phase 1a only) Participants who have metastatic disease which has progressed during or after approved standard therapies or are intolerant to approved therapies, or for which the participant refuses or is ineligible for standard therapy.\n4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.\n5. Life expectancy ≥12 weeks.\n6. Participants with adequate organ function\n7. No potential for childbearing or agree to use adequate contraception\n8. Ability to understand the study purpose and procedures and have the willingness to sign a written informed consent document.\n9. (Phase 1b only ) Must have histologically confirmed advanced or metastatic NSCLC without actionable genomic alteration that have approved therapies in the location where the participant's live and with measurable disease as determined by RECIST v1.1\n\nKey Exclusion Criteria:\n\n1. Clinically significant cardiac disease or cardiac failure.\n2. Untreated or unstable brain or central nervous system (CNS) metastases or Leptomeningeal disease\n3. Participants with any concurrent active malignancies\n4. Has received prior therapy targeting LILRB or immunoglobulin-like transcript pathway.\n5. History of life-threatening toxicity related to prior immune therapy\n6. Has not recovered to ≤ Grade 1 or baseline from AEs and\u002For complications from prior surgical intervention or any anti-cancer treatment before starting study treatment\n7. Participants must not have an active, known, or suspected autoimmune disease.\n8. Evidence of active infection requiring IV antibiotic treatment ≤7 days prior to initiation of study treatment therapy (does not apply to viral infections that are presumed to be associated with the underlying tumor type required for study entry).\n9. Pregnant or lactating or expecting to conceive a child during the study or within 6 months after the last dose of study intervention.\n10. Any condition that would, in the Investigator's judgment, interfere with full participation in the study, including administration of study intervention and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.\n11. (Phase 1b only) Participants who were previously exposed to atezolizumab","ALL","18 Years",{"count":20,"type":21},76,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a Phase 1a\u002F1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)\u002FRecommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109 as monotherapy in participants with advanced and\u002For metastatic non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), urothelial carcinoma, or malignant melanoma and no available standard of care treatment options, and as combination therapy with atezolizumab in participants with advanced and\u002For metastatic NSCLC.",[27,28,29,30,31],"Non-small Cell Lung Cancer(NSCLC)","Head and Neck Squamous Cell Carcinoma(HNSCC)","Renal Cell Carcinoma(RCC)","Urothelial Carcinoma","Malignant Melanoma",[33],"solid tumor","RECRUITING","2025-11-19",{"date":37,"type":38},"2025-11-24","ACTUAL",{"date":40,"type":38},"2024-06-05",{"date":42,"type":21},"2028-03",{"name":44,"class":45},"LG Chem","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":46},"100498101","phase-2-neoadjuvant-wx-0593-in-resectable-alk-positive-or-ros1-positive-non-small-cell-lung-cancer-100498101","NCT05765877","Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer","Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer : a Single-arm, Exploratory Trial","Inclusion Criteria:\n\n* Histologically confirmed non-small cell lung cancer (NSCLC).\n* ALK-positive or ROS1-positive NSCLC in Stage IB-IIIA (according to the 8th American Joint Committee on Cancer TNM edition), as assessed by investigator.\n* Complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by a MDT evaluation (which should include a thoracic surgeon, specialized in oncologic procedures).\n* ECOG Performance Status of 0-1.\n* At least one measurable lesion according to RECIST 1.1.\n* Adequate organ and marrow function.\n\nExclusion Criteria:\n\n* Prior treatment with any systemic anti-cancer therapy for NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug.\n* Prior treatment with ALK TKI or ROS1 TKI.\n* Prior treatment with local radiotherapy.\n* Mixed small cell and NSCLC histology.\n* Patients who are candidates to undergo only segmentectomies or wedge resections.",{"count":55,"type":21},26,[57],"PHASE2","This is a single-arm, exploratory trial to evaluate the efficacy and safety of neoadjuvant WX-0593 in patients with resectable ALK-positive or ROS1- positive non-small cell lung cancer(NSCLC).",[60],"Non-Small Cell Lung Cancer(NSCLC)","2025-06-11",{"date":63,"type":38},"2025-06-12",{"date":65,"type":38},"2023-03-01",{"date":67,"type":21},"2029-03",{"name":69,"class":70},"Pingping Song","OTHER",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100574271","a-study-on-the-efficacy-of-immunotherapy-the-occurrence-and-severity-of-adverse-reactions-in-patients-with-non-small-cell-lung-cancer-in-high-altitude-areas-100574271","NCT06757114","A Study on the Efficacy of Immunotherapy, the Occurrence and Severity of Adverse Reactions in Patients with Non-small Cell Lung Cancer in High-altitude Areas","A Study on the Multi-omic Factors Influencing the Efficacy of Immunotherapy and Adverse Reactions of Immunotherapy in Patients with Primary Non-small Cell Lung Cancer in High-altitude Areas","Inclusion Criteria:\n\n* (1) Patients with primary non-small cell lung cancer (adenocarcinoma\u002Fsquamous cell carcinoma\u002Fadenosquamous cell carcinoma\u002Flarge cell lung cancer\u002Fothers) with clear cellular\u002Fhistopathological evidence; (2) Primary non-small cell lung cancer of any stage receiving immunotherapy for the first time; (3) Patients who have undergone at least 2 cycles of immunotherapy during the treatment period and have undergone one efficacy evaluation; (4) Patients with at least one evaluable target lesion (except for those with uncontrolled brain metastases) according to Response Evaluation Criteria for Solid T Tumors (RECIST, version 1.1); (5) Voluntary participation in research and strong willingness to cooperate; (6) has been residing in Qinghai Province since birth; (7) Have been residing in Shaanxi Province since birth; (8) Be at least 18 years old;\n\nExclusion Criteria:\n\n1. Patients with unknown histopathological type were excluded;\n2. Patients with unclear diagnosis and treatment information and immunotherapy-related adverse reactions;\n3. Patients with bipolar\u002Fmultiple primary non-small cell lung cancer with other tumors were excluded;\n4. Patients who are unwilling to join the study and have poor willingness to cooperate;\n5. Patients who migrated to Qinghai or Shaanxi from different altitudes and had a history of migration between the two provinces were excluded;\n6. exclude patients with a history of emigration from parents;\n7. Patients who have received immunotherapy for other tumors in the past;\n8. Prior immunosuppressive therapy prior to exclusion",{"count":79,"type":21},200,"OBSERVATIONAL","As a major disease with high incidence and mortality rate, lung cancer seriously threatens the health of our people and causes a huge burden of disease. In recent years, with the widespread use of immune checkpoint inhibitors (ICIs), great progress has been made in the treatment of lung cancer, which has brought significant survival benefits to patients. Although ICI has greatly improved the prognosis of lung cancer patients, due to the complexity of the mechanism of action of ICI and the heterogeneity within the tumor, the benefit population of treatment is relatively limited, and some patients are still at risk of primary drug resistance and tumor hyperprogression.In this study, we aimed to compare the differences in the efficacy and adverse reactions of immunotherapy in patients with advanced non-small cell lung cancer at high and low altitudes, and to find out the relevant factors from multiple omics such as imaging, pathology, and genetics, so as to solve the problem of immunotherapy resistance",[27],"NOT_YET_RECRUITING","2025-01-01",{"date":86,"type":38},"2025-01-03",{"date":84,"type":21},{"date":89,"type":21},"2025-06-30",{"name":91,"class":70},"Second Affiliated Hospital of Xi'an Jiaotong University"]